CordenPharma creates Technology and Science Advisory Board to drive company forward


The board is comprised of eight renowned experts from academia and industry, who will provide strategic guidance and scientific expertise to drive forward

CordenPharma creates Technology and Science Advisory Board to drive company forward

CDMO CordenPharma has created a new Technology & Science Advisory Board (TSAB) with eight world-class experts from academia and industry, who will provide strategic guidance and scientific expertise to drive forward the company's continued growth and innovation.

The formation of the Technology & Science Advisory Board was born out of CordenPharma's commitment to stay at the forefront of the pharmaceutical and biotechnology industries. By harnessing the knowledge and insights of renowned scientists and industry leaders coming from both academia and commercial sectors, the company aims to enhance its capabilities in the efficient development and manufacturing of APIs, Lipid Excipients, Drug Products, and Integrated Supply to support the complex modalities of its broad pharmaceutical customer base.

CordenPharma’s TSAB brings together eight scientific experts from various disciplines, including chemistry, pharmacology, biotechnology, and regulatory affairs.

Their collective expertise will provide valuable insights into emerging trends, cutting-edge technologies, and regulatory advancements across all six CordenPharma technology platforms. This collaboration will further enable the CDMO to anticipate industry developments and ensure its readiness to meet the evolving needs of customers and their life-saving medicines.

The eight new board members include internationally renowned experts in the fields of drug development, peptides, oligonucleotides, lipids, injectable Lipid NanoParticles (LNPs), RNA drug delivery, highly potent Oral Solid Dose (OSD), flow chemistry, and small molecules. While the board will initially look at science-focused areas, they will also explore bioinformatics, including AI and machine learning, in the future.

CordenPharma 2023 Technology & Science Advisory Board Members

  • Dr José de Chastonay, Independent Consultant for Strategic M&A and Business Development (Portugal / Switzerland) - Decades of peptide industry leadership experience with emphasis on corporate development, business integration as well as operational and commercial activities.
  • Professor Dr Christian Oliver Kappe, Professor of Chemistry, University of Graz (Austria) - Recognised as one of the most experienced experts in the field of flow chemistry.
  • Professor Dr Hiroshi Kikuchi, President of DDS Strategy Firm (Japan) - The leading lipid expert in Japan, connected to all important lipid experts in the world.
  • Professor Dr Olivia Merkel, Professor and Chair of Drug Delivery, LMU Munich (Germany) - Highly recognised expert in drug delivery for RNA and treatment of lung diseases.
  • Professor Dr Jean-Christophe M. Monbaliu, Professor of Organic Chemistry, Centre for Integrated Technology and Organic Synthesis, University of Liège (Belgium) - Highly recognised flow chemistry expert with a strong background in multistep flow processes (lab and pilot scales).
  • Dr Christoph Rosenbohm, MBA, Chief Technology Officer (CTO), Aloop Therapeutics (Denmark) – Long-standing experience in the field of oligonucleotides. 
  • Professor Dr Roderich Süssmuth, Rudolf-Wiechert-Professor and Chair of Biological Chemistry, Technical University Berlin (Germany) - Highly recognized expert of peptides and synthesis of natural products.
  • Professor Dr Karl Wagner, Professor of Pharmaceutical Technology and Biopharmacy, University of Bonn (Germany) - Expert in solubility enhancement, OSD in general and predictive biopharmaceutical tools.
Sign up for your free email newsletter

Dr Michael Quirmbach, CEO & President at CordenPharma, said: “CordenPharma is honored to have the opportunity to work with these distinguished scientific experts. We look forward to leveraging their renowned experience to continue driving innovation across our six technology platforms and delivering exceptional value to support the complex modalities of our pharmaceutical and biotech customers.”